, Le prérequis essentiel à la réalisation d'un suivi thérapeutique, est de disposer de techniques de dosage validées et performantes, permettant de monitorer la concentration d'une substance

, D'autres techniques telles que la chromatographie liquide haute performance couplé à l'ultraviolet (HPLC, UPLC) peuvent constituer des alternatives possibles pour les laboratoires qui ne seraient pas équipés de LC-MS/MS, plus onéreuse et plus sophistiquée 75

A. R. Tu, . Rein, and . Org, Tumeurs du Rein:: Généralités :: Qu'est

, Les cancers en France en 2018 -L'essentiel des faits et chiffres (édition, 2019.

, ETKAFR19

, Synthèse -Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 -Ref : SYNINCNAT2019

, Article -Bulletin épidémiologique hebdomadaire

, Données globales d'épidémiologie des cancers -Epidémiologie des cancers

, Projection de l'incidence et de la mortalité en France métropolitaine en 2017 -Rapport technique -Ref : RAINCMETRO17

A. R. Tu, . Rein, and . Org, Tumeurs du Rein :: Epidémiologie -Facteurs de risque

F. Islami, M. Stoklosa, J. Drope, and A. Jemal, Global and Regional Patterns of Tobacco Smoking and Tobacco Control Policies, Eur. Urol. Focus, vol.1, pp.3-16, 2015.

J. Benichou, W. H. Chow, J. K. Mclaughlin, J. S. Mandel, and J. F. Fraumeni, Population attributable risk of renal cell cancer in Minnesota, Am. J. Epidemiol, vol.148, pp.424-430, 1998.

M. G. Cumberbatch, M. Rota, J. W. Catto, and C. Vecchia, The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks, Eur. Urol, vol.70, pp.458-466, 2016.

N. Kroeger, Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival, Cancer, vol.118, pp.1795-1802, 2012.

J. Gelfond, Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial, Urol. Oncol, vol.36, 2018.

J. D. Hunt, O. L. Van-der-hel, G. P. Mcmillan, P. Boffetta, and P. Brennan, Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies, Int. J. Cancer, vol.114, pp.101-108, 2005.

A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet Lond. Engl, vol.371, pp.569-578, 2008.

W. T. Lowrance, Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies, BJU Int, vol.105, pp.16-20, 2010.

J. M. Yuan, J. E. Castelao, M. Gago-dominguez, R. K. Ross, and M. C. Yu, Hypertension, obesity and their medications in relation to renal cell carcinoma, Br. J. Cancer, vol.77, pp.1508-1513, 1998.

V. W. Setiawan, D. O. Stram, A. M. Nomura, L. N. Kolonel, and B. E. Henderson, Risk factors for renal cell cancer: the multiethnic cohort, Am. J. Epidemiol, vol.166, pp.932-940, 2007.

S. Weikert, Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition, Am. J. Epidemiol, vol.167, pp.438-446, 2008.

J. Correas, D. Joly, D. Chauveau, S. Richard, and O. Hélénon,

, J. Radiol, vol.92, pp.308-322, 2011.

S. Richard, Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease, Neurosurg. Rev, vol.23, pp.1-22, 2000.

M. D. Urologie, . Tumeurs, and . Rein, Formes héréditaires des cancers du rein et dépistage génétique, 2018.

B. Ljungberg, The epidemiology of renal cell carcinoma, Eur. Urol, vol.60, pp.615-621, 2011.

S. Karami, Occupational trichloroethylene exposure and kidney cancer risk: a metaanalysis, Occup. Environ. Med, vol.69, pp.858-867, 2012.

A. Méjean and T. Lebret, Prise en charge of metastatic renal carcinoma

, Progres En Urol. J

, Assoc. Francaise Urol. Soc. Francaise Urol, vol.18, pp.298-308, 2008.

B. Albouy, M. Gross-goupil, B. Escudier, and C. Massard,

, Bull. Cancer (Paris), vol.97, pp.17-28, 2010.

H. Moch, A. L. Cubilla, P. A. Humphrey, V. E. Reuter, and T. M. Ulbright, The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours, Eur. Urol, vol.70, pp.93-105, 2016.

J. Edeline, C. Vigneau, J. Patard, and N. Rioux-leclercq,

, Bull. Cancer (Paris), vol.97, pp.5-15, 2010.

M. Urologie and . De, Voies moléculaires de l'angiogenèse tumorale et nouvelles approches thérapeutiques ciblées dans le cancer du rein, 2018.

K. Bensalah,

, Progres En Urol. J. Assoc. Francaise Urol. Soc. Francaise Urol, vol.27, issue.1, pp.27-51, 2016.

M. Urologie and . De, Recommandations françaises du Comité de Cancérologie de l'AFU -Actualisation, 2018.

L. Marconi, Systematic Review and Meta-analysis of Diagnostic Accuracy of
URL : https://hal.archives-ouvertes.fr/hal-01262680

, Percutaneous Renal Tumour Biopsy, Eur. Urol, vol.69, pp.660-673, 2016.

C. Webber, Improving the TNM classification: findings from a 10-year continuous literature review, Int. J. Cancer, vol.135, pp.371-378, 2014.

S. Eggener, TNM staging for renal cell carcinoma: time for a new method, Eur. Urol, vol.58, pp.519-521, 2010.

F. Desmots, Scores morphométriques des tumeurs rénales : intérêt en pratique courante, 2013.

V. Ficarra, Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery, Eur. Urol, vol.56, pp.786-793, 2009.

A. Kutikov, R. G. Uzzo, and R. E. The, nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth, J. Urol, vol.182, pp.844-853, 2009.

M. N. Simmons, C. B. Ching, M. K. Samplaski, C. H. Park, and I. S. Gill, Kidney tumor location measurement using the C index method, J. Urol, vol.183, pp.1708-1713, 2010.

E. Scosyrev, E. M. Messing, R. Sylvester, S. Campbell, and H. Van-poppel, Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904

, Eur. Urol, vol.65, pp.372-377, 2014.

U. Capitanio, End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline, Eur. Urol, vol.70, pp.558-561, 2016.

U. Capitanio, Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function, Eur. Urol, vol.67, pp.683-689, 2015.

C. Gratzke, Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma, BJU Int, vol.104, pp.470-475, 2009.

B. R. Lane and I. S. Gill, 7-year oncological outcomes after laparoscopic and open partial nephrectomy, J. Urol, vol.183, pp.473-479, 2010.

M. Muramaki, H. Miyake, I. Sakai, and M. Fujisawa, Prognostic Factors Influencing

, Postoperative Development of Chronic Kidney Disease in Patients with Small Renal Tumors who Underwent Partial Nephrectomy, Curr. Urol, vol.6, pp.129-135, 2013.

M. N. Simmons, C. J. Weight, and I. S. Gill, Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes, Urology, vol.73, pp.1077-1082, 2009.

B. C. Leibovich, Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy, J. Urol, vol.171, pp.1066-1070, 2004.

J. Patard, Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication, Eur. Urol, vol.52, pp.148-154, 2007.

U. Capitanio, Lymph node dissection in renal cell carcinoma, Eur. Urol, vol.60, pp.1212-1220, 2011.

N. B. Haas, Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial, JAMA Oncol, vol.3, pp.1249-1252, 2017.

R. J. Motzer, Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.35, pp.3916-3923, 2017.

A. Ravaud, Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

. Engl, J. Med, vol.375, pp.2246-2254, 2016.

G. H. Mickisch, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet Lond. Engl, vol.358, pp.966-970, 2001.

R. C. Flanigan, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N. Engl. J. Med, vol.345, pp.1655-1659, 2001.

A. Bex, Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial, JAMA Oncol, vol.5, pp.164-170, 2019.

A. Méjean, Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

. Engl, J. Med, vol.379, pp.417-427, 2018.

B. Escudier, Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, N. Engl. J. Med, vol.356, pp.125-134, 2007.

R. J. Motzer, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl

, J. Med, vol.356, pp.115-124, 2007.

R. J. Motzer, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.378, pp.1277-1290, 2018.

T. K. Choueiri, Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203

. Cabosun-trial, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.35, pp.591-597, 2017.

, Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM

,

T. K. Choueiri, Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, Lancet Oncol, vol.17, pp.917-927, 2016.

R. J. Motzer, Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J

. Med, , vol.369, pp.722-731, 2013.

L. C. Harshman and S. Srinivas, The bevacizumab experience in advanced renal cell carcinoma

, OncoTargets Ther, vol.3, pp.179-189, 2010.

E. Zanardi, Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma, Ther. Adv. Urol, vol.7, pp.152-161, 2015.

T. E. Hutson, Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial, Clin. Genitourin. Cancer, vol.15, pp.72-76, 2017.

, Résultats de recherche d'essais cliniques -Le registre des essais cliniques

. Ct-15738_cabometyx_pic_ins_avispostobs_ct15738 and . Pdf,

. Ct-17224_cabometyx_pic_ei_avis3_ct17224 and . Pdf,

E. Schmidt, Cabozantinib Versus Standard-of-Care Comparators in the Treatment of

, Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis, Target. Oncol, vol.13, pp.205-216, 2018.

, Résultats de recherche d'essais cliniques -Le registre des essais cliniques

, Les thérapies ciblées dans le traitement du cancer en 2015 -État des lieux et enjeux -Ref

, APDEMOMED16

S. Zaibet, Enjeux et écueils des thérapies ciblées orales en pratique clinique quotidienne : 5 e journée de pharmacologie des anti-tumoraux

N. Widmer, Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies, Eur. J. Cancer Oxf. Engl, vol.50, pp.2020-2036, 1990.

L. A. Decosterd, Therapeutic drug monitoring of targeted anticancer therapy

. Med, , vol.9, pp.887-893, 2015.

N. Widmer, Imatinib plasma levels: correlation with clinical benefit in GIST patients

, J. Cancer, vol.102, pp.1198-1199, 2010.

B. E. Houk, Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

, Cancer Chemother. Pharmacol, vol.66, pp.357-371, 2010.

S. Faivre, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.25-35, 2006.

Y. Ishida, Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia, Eur. J. Clin. Pharmacol, vol.72, pp.185-193, 2016.

S. Lacy, Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma, Cancer Chemother. Pharmacol, vol.81, pp.1061-1070, 2018.

C. N. Sternberg, Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the

, Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.24, pp.3005-3013, 2018.

P. Gougis, Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use, Crit. Rev. Oncol. Hematol, vol.141, pp.112-124, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02289357

H. Klümpen, C. F. Samer, R. H. Mathijssen, J. H. Schellens, and H. Gurney, Moving towards dose individualization of tyrosine kinase inhibitors, Cancer Treat. Rev, vol.37, pp.251-260, 2011.

J. H. Beumer, Without therapeutic drug monitoring, there is no personalized cancer care

, Clin. Pharmacol. Ther, vol.93, pp.228-230, 2013.

. Who-|-adherence, . Long-term, and . Therapies, EVIDENCE FOR ACTION

U. Yanamandra, Variation in Adherence Measures to Imatinib Therapy, J. Glob. Oncol, vol.4, pp.1-10, 2018.

D. Marin, Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib, J. Clin

, Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.2381-2388, 2010.

C. C. Murphy, L. K. Bartholomew, M. Y. Carpentier, S. M. Bluethmann, and S. W. Vernon,

, Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review, Breast Cancer Res. Treat, vol.134, pp.459-478, 2012.

L. Noens, Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood, vol.113, pp.5401-5411, 2009.

E. Cardoso, C. Csajka, M. P. Schneider, and N. Widmer,

, Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs, Clin. Pharmacokinet, vol.57, pp.1-6, 2018.

R. Haque, Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO, J. Am. Pharm. Assoc. JAPhA, vol.57, 2017.

M. Hornecker, Saturable absorption of sorafenib in patients with solid tumors: a population model, Invest. New Drugs, vol.30, 1991.

H. Yu, Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients, Clin. Pharmacokinet, vol.56, pp.293-303, 2017.

R. W. Van-leeuwen, T. Van-gelder, R. H. Mathijssen, and F. G. Jansman, Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective, Lancet Oncol, vol.15, pp.315-326, 2014.

C. Yoo, Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.1554-1559, 2010.

K. Kim, Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability, Cancer Chemother. Pharmacol, vol.68, pp.285-291, 2011.

I. Judson, Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group, Cancer Chemother. Pharmacol, vol.55, pp.379-386, 2005.

J. Arrondeau, Sorafenib exposure decreases over time in patients with hepatocellular carcinoma, Invest. New Drugs, vol.30, pp.2046-2049, 2012.

S. M. Makhtar, A. Husin, A. A. Baba, and R. Ankathil, Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients, J. Genet, vol.97, pp.835-842, 2018.

Y. Chu, Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma, PloS One, vol.10, p.134102, 2015.

J. M. Kremer, J. Wilting, and L. H. Janssen, Drug binding to human alpha-1-acid glycoprotein in health and disease, Pharmacol. Rev, vol.40, pp.1-47, 1988.

C. Gambacorti-passerini, Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571, J. Natl. Cancer Inst, vol.92, pp.1641-1650, 2000.

M. Tod, Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients, Pharm. Res, vol.28, pp.3199-3207, 2011.

O. Huillard, Sarcopenia and body mass index predict sunitinib-induced early doselimiting toxicities in renal cancer patients, Br. J. Cancer, vol.108, pp.1034-1041, 2013.

P. Di-gion, Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles, Clin. Pharmacokinet, vol.50, pp.551-603, 2011.

S. Zhou, Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I, Clin. Pharmacokinet, vol.48, pp.689-723, 2009.

A. Sanchez-spitman, Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.37, pp.636-646, 2019.

T. E. Mürdter, Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma, Clin. Pharmacol. Ther, vol.89, pp.708-717, 2011.

H. Ba and . Le, Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake, Pharmacogenomics, vol.21, pp.173-179, 2020.

P. Miner, P. O. Katz, Y. Chen, and M. Sostek, Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study, Am. J. Gastroenterol, vol.98, pp.2616-2620, 2003.

A. R. Tan, Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors, Cancer Chemother. Pharmacol, vol.71, pp.1635-1643, 2013.

H. Kletzl, Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine, Anticancer. Drugs, vol.26, pp.565-572, 2015.

K. M. Koch, Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients, Clin. Pharmacol. Drug Dev, vol.2, pp.336-341, 2013.

S. Durmus, J. J. Hendrikx, and A. H. Schinkel, Apical ABC transporters and cancer chemotherapeutic drug disposition, Adv. Cancer Res, vol.125, pp.1-41, 2015.

, Pharmacokinetic Drug Interactions of Afatinib With Rifampicin and Ritonavir -PubMed

A. Rowland, Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure, Expert Opin. Drug Metab. Toxicol, vol.13, pp.31-49, 2017.

P. Gougis, Clinical pharmacology of anti-angiogenic drugs in oncology, Crit. Rev. Oncol. Hematol, vol.119, pp.75-93, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01662030

J. F. Deeken, Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib, Cancer Chemother. Pharmacol, vol.76, pp.813-819, 2015.

S. Chhun, Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers, Br. J. Clin. Pharmacol, vol.68, pp.226-237, 2009.

O. Mir, V. Poinsignon, M. Arnedos, S. Delaloge, and A. Paci, Pharmacokinetic interaction involving fenofibrate and everolimus, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.26, pp.248-249, 2015.

N. P. Van-erp, Marginal increase of sunitinib exposure by grapefruit juice, Cancer Chemother. Pharmacol, vol.67, pp.695-703, 2011.

P. Smith, John's wort on the pharmacokinetics and protein binding of imatinib mesylate, Pharmacotherapy, vol.24, pp.1508-1514, 2004.

J. Ge, Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability, J. Mol. Med. Berl. Ger, vol.89, pp.595-602, 2011.

S. Zevin and N. L. Benowitz, Drug interactions with tobacco smoking. An update, Clin. Pharmacokinet, vol.36, pp.425-438, 1999.

M. Hamilton, Effects of smoking on the pharmacokinetics of erlotinib, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.12, pp.2166-2171, 2006.

A. N. Hughes, Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.1220-1226, 2009.

N. Van-erp, Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.14, pp.8308-8313, 2008.

S. L. Groenland, R. H. Mathijssen, J. H. Beijnen, A. D. Huitema, and N. Steeghs, Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine, Eur. J. Clin. Pharmacol, vol.75, pp.1309-1318, 2019.

M. Steffens, Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash, Eur. J. Cancer Oxf. Engl, vol.55, pp.131-139, 1990.

S. Bouchet, Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory, Fundam. Clin. Pharmacol, vol.27, pp.690-697, 2013.

R. B. Verheijen, J. H. Beijnen, J. H. Schellens, A. D. Huitema, and N. Steeghs, Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clin. Pharmacokinet, vol.56, pp.987-997, 2017.

L. Cabel, Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study, Fundam. Clin. Pharmacol, vol.32, pp.98-107, 2018.

P. Boudou-rouquette, Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis, The Oncologist, vol.17, pp.1204-1212, 2012.

M. Rousset, Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma, Clin. Chim. Acta Int. J. Clin. Chem, vol.472, pp.26-29, 2017.

K. Kim, Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia, PloS One, vol.14, p.226552, 2019.

E. Perucca, Is there a role for therapeutic drug monitoring of new anticonvulsants?, Clin. Pharmacokinet, vol.38, pp.191-204, 2000.

C. B. Eap, Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity, Eur. J. Clin. Pharmacol, vol.60, pp.237-246, 2004.

J. Li, CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors, J. Natl. Cancer Inst, vol.98, pp.1714-1723, 2006.

M. V. Relling, Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus, J. Natl. Cancer Inst, vol.91, 1999.

H. L. Mcleod, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.3227-3233, 2010.

M. Boisdron-celle, A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification, Semin. Oncol, vol.44, pp.24-33, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01819425

U. Amstutz, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for

F. Dihydropyrimidine-dehydrogenase-genotype and . Dosing, Update. Clin. Pharmacol. Ther, vol.103, pp.210-216, 2017.

N. P. Van-erp, Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.4406-4412, 2009.

S. George, Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.23, pp.3180-3187, 2012.

D. Sabanathan, Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring, Cancer Chemother. Pharmacol, vol.80, pp.385-393, 2017.

M. Tiseo, Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC), Lung Cancer Amst. Neth, vol.83, pp.265-271, 2014.

J. R. Brahmer, Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503), Eur. J. Cancer Oxf. Engl, vol.50, pp.302-308, 1990.

A. C. Mita, Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer, Br. J. Cancer, vol.105, pp.938-944, 2011.

D. Miles, N. L. Jumbe, S. Lacy, and L. Nguyen, Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis, Clin. Pharmacokinet, vol.55, pp.93-105, 2016.

Q. Su, An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study, J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci, vol.985, pp.119-123, 2015.

L. Ren, A sensitive LC-MS/MS method for simultaneous determination of cabozantinib and its metabolite cabozantinib N-oxide in rat plasma and its application in a pharmacokinetic study, Biomed. Chromatogr. BMC, vol.32, p.4227, 2018.

W. X. , Pharmacokinetics and tissue distribution model of cabozantinib in rat

S. Lacy, Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites, Drug Metab. Dispos. Biol. Fate Chem, vol.43, pp.1190-1207, 2015.

A. S. Abdelhameed, M. W. Attwa, and A. A. Kadi, An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma, Biomed. Chromatogr. BMC, vol.31, 2017.

, Ipsen annonce des résultats préliminaires positifs de l'étude pivotale de phase III CheckMate -9ER évaluant CABOMETYX® (cabozantinib) en combinaison avec Opdivo® (nivolumab) chez des patients atteints d'un carcinome rénal avancé non précédemment traité